| Multiple Sclerosis |
1 |
1 |
| Interferon Beta |
0 |
0.57 |
| Face |
0 |
0.29 |
| Multiple Sclerosis Relapse |
0 |
0.29 |
| Pathogenesis |
0 |
0.29 |
| Prognosis |
0 |
0.29 |
| Cognitive Impairment |
0 |
0.2 |
| Genetic Disorders |
0 |
0.2 |
| Blood |
0 |
0.14 |
| Disability |
0 |
0.14 |
| Disease-Modifying Therapy |
0 |
0.14 |
| Genetics |
0 |
0.14 |
| Glatiramer Acetate |
0 |
0.14 |
| Impairment |
0 |
0.14 |
| Insurance |
0 |
0.14 |
| Medical Innovations |
0 |
0.14 |
| Movement Disorder |
0 |
0.14 |
| Multiple Sclerosis Treatment |
0 |
0.14 |
| Myelin |
0 |
0.14 |
| New York |
0 |
0.14 |
| Nursing Homes |
0 |
0.14 |
| Tolerance |
0 |
0.14 |
| Young Adult |
0 |
0.14 |
| Biologic Therapy |
0 |
0.13 |
| Genomic Medicine |
0 |
0.05 |
| Healthcare and Medical Technology |
0 |
0.05 |
| Revenue and Practice Management |
0 |
0.04 |
| Mild Cognitive Impairment |
0 |
0.03 |
| Muscular Dystrophy |
0 |
0.03 |